Biotech Values

[DewDiligence]

don't understand...value of ENTA's continued drug development for the HCV field.

ENTA's internal development in HCV consists of only one program: EDP-494, which has a different MoA—and a higher barrier to resistance—than any HCV drug on the market.

It won't cost ENTA much to find out if EDP-494 is a worthwhile addend to somebody's HCV regimen.